PSI-6130

Add links
Source: Wikipedia, the free encyclopedia.
PSI-6130
Clinical data
ATC code
  • none
Identifiers
  • 4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
JSmol)
  • C[C@]1([C@@H]([C@H](O[C@H]1n2ccc(nc2=O)N)CO)O)F
  • InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
  • Key:NYPIRLYMDJMKGW-VPCXQMTMSA-N
  (verify)

PSI-6130 is an experimental treatment for

NS5B.[2]

PSI-6130 is currently being developed by

Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128.[3] R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.[4]

References

  1. PMID 16107149
    .
  2. S2CID 22710780
    .
  3. doi:10.1358/dof.2009.034.04.1367744
    .
  4. S2CID 28977802
    .
drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=PSI-6130&oldid=1216104992"